Sen. Bernie Sanders (I-Vt.) speaks during a hearing on March 14, 2024 in Washington, D.C.
Sanders Says Novo Nordisk CEO to Testify About 'Outrageously High' Drug Prices
"The committee looks forward to Mr. Jørgensen answering a very simple question: Why does he think it's acceptable to charge Americans up to 10 or 15 times more for Ozempic and Wegovy than people in Europe and other major countries?" said Sen. Bernie Sanders.
In his latest move aimed at holding the Danish pharmaceutical giant Novo Nordisk accountable for the high price of its weight loss medications, U.S. Sen. Bernie Sanders on Monday announced the CEO of the company will soon testify before the Senate committee he chairs.
Lars Jørgensen is scheduled to appear before the Senate Health, Education, Labor, and Pensions (HELP) Committee on September 24 to discuss what Sanders called "the outrageously high prices that Novo Nordisk charges Americans for their blockbuster drugs, Ozempic and Wegovy."
As Common Dreams reported last month, Americans pay hundreds of dollars more for the two drugs, which treat Type 2 Diabetes and weight management, than people in other wealthy countries with government-funded healthcare programs.
"Novo Nordisk currently charges Americans with Type 2 diabetes $969 a month for Ozempic, while this same exact drug can be purchased for just $155 in Canada, $122 in Denmark, and just $59 in Germany," said Sanders (I-Vt.). "Incredibly, Novo Nordisk also charges Americans with obesity $1,349 a month for Wegovy, while this same exact product can be purchased for just $186 in Denmark, $140 in Germany, and $92 in the United Kingdom."
"Wegovy is a 'game changer' weight loss drug. That doesn't mean much to the millions of people who can't afford it."
"The committee looks forward to Mr. Jørgensen answering a very simple question: Why does he think it's acceptable to charge Americans up to 10 or 15 times more for Ozempic and Wegovy than people in Europe and other major countries?" said the senator.
Sanders had been planning to hold a vote on subpoenaing Jørgensen before he indicated he would be open to testifying before the committee earlier this month.
In April, the North Carolina state health plan, used by 20,000 teachers and other state employees, announced it would discontinue coverage for Wegovy and similar medications because the price "would require them to double insurance premiums."
Earlier this month, Blue Cross Blue Shield of Michigan, the state's largest insurer, also said it would end coverage of glucagon-like peptide-1 (GLP-1) obesity drugs—a decision that could impact roughly 10,000 people in the state who use the medications.
"Wegovy is a 'game changer' weight loss drug," said Sanders at the time. "That doesn't mean much to the millions of people who can't afford it."
We are at a crossroads
This country and this world are at a monumental crossroads. In a few short weeks, US voters will have an opportunity to beat back the forces of fascism and confront the billionaires who are rigging the economy, our media system, and our democracy, making it increasingly impossible for ordinary people to get by. We’re not just talking about the election. We’re talking about what must be done once these fascist elements are vanquished from power. We need a bolder set of solutions than what either major party has so far been willing to offer and a working-class movement ready to fight like hell for it. Trump didn't emerge from nowhere. The conditions that fueled MAGA authoritarianism were created by decades of radical neoliberal economic policies and a corrupt political system dominated by corporate interests. They slashed taxes on the super-rich, promising that the benefits would trickle down. They said giveaways to the corporate titans would make life more affordable for the rest of us. It was all bullshit. And when a bitter, betrayed populace searches for someone to blame, right-wing demagogues have little trouble finding scapegoats. People know when they're being lied to, but you won't hear any of this from the corporate media. Only independent journalism—powered and funded by people who believe in building a better world—can deliver truly trustworthy daily news. Our Fall Campaign is underway, and we need your help. To power our newsroom through the rest of the year, we need to raise $125,000 by midnight on October 31. So if you share our vision, please contribute whatever you can to sustain our work. |
In his latest move aimed at holding the Danish pharmaceutical giant Novo Nordisk accountable for the high price of its weight loss medications, U.S. Sen. Bernie Sanders on Monday announced the CEO of the company will soon testify before the Senate committee he chairs.
Lars Jørgensen is scheduled to appear before the Senate Health, Education, Labor, and Pensions (HELP) Committee on September 24 to discuss what Sanders called "the outrageously high prices that Novo Nordisk charges Americans for their blockbuster drugs, Ozempic and Wegovy."
As Common Dreams reported last month, Americans pay hundreds of dollars more for the two drugs, which treat Type 2 Diabetes and weight management, than people in other wealthy countries with government-funded healthcare programs.
"Novo Nordisk currently charges Americans with Type 2 diabetes $969 a month for Ozempic, while this same exact drug can be purchased for just $155 in Canada, $122 in Denmark, and just $59 in Germany," said Sanders (I-Vt.). "Incredibly, Novo Nordisk also charges Americans with obesity $1,349 a month for Wegovy, while this same exact product can be purchased for just $186 in Denmark, $140 in Germany, and $92 in the United Kingdom."
"Wegovy is a 'game changer' weight loss drug. That doesn't mean much to the millions of people who can't afford it."
"The committee looks forward to Mr. Jørgensen answering a very simple question: Why does he think it's acceptable to charge Americans up to 10 or 15 times more for Ozempic and Wegovy than people in Europe and other major countries?" said the senator.
Sanders had been planning to hold a vote on subpoenaing Jørgensen before he indicated he would be open to testifying before the committee earlier this month.
In April, the North Carolina state health plan, used by 20,000 teachers and other state employees, announced it would discontinue coverage for Wegovy and similar medications because the price "would require them to double insurance premiums."
Earlier this month, Blue Cross Blue Shield of Michigan, the state's largest insurer, also said it would end coverage of glucagon-like peptide-1 (GLP-1) obesity drugs—a decision that could impact roughly 10,000 people in the state who use the medications.
"Wegovy is a 'game changer' weight loss drug," said Sanders at the time. "That doesn't mean much to the millions of people who can't afford it."
- Sanders Launches Probe of 'Outrageously Overpriced' Ozempic and Wegovy ›
- Sanders Warns 'Unjustifiably High' Prices of Weight Loss Drugs Could Bankrupt US Health System ›
- US Drug Prices Still Far Higher Than Other Nations' Even After Medicare Talks | Common Dreams ›
- Ahead of Senate Hearing, Doctors Decry 'Exorbitant' Cost of Ozempic and Wegovy | Common Dreams ›
- Sanders Calls BS on Novo Nordisk Excuses for Sky-High Prices of Ozempic, Wegovy | Common Dreams ›
In his latest move aimed at holding the Danish pharmaceutical giant Novo Nordisk accountable for the high price of its weight loss medications, U.S. Sen. Bernie Sanders on Monday announced the CEO of the company will soon testify before the Senate committee he chairs.
Lars Jørgensen is scheduled to appear before the Senate Health, Education, Labor, and Pensions (HELP) Committee on September 24 to discuss what Sanders called "the outrageously high prices that Novo Nordisk charges Americans for their blockbuster drugs, Ozempic and Wegovy."
As Common Dreams reported last month, Americans pay hundreds of dollars more for the two drugs, which treat Type 2 Diabetes and weight management, than people in other wealthy countries with government-funded healthcare programs.
"Novo Nordisk currently charges Americans with Type 2 diabetes $969 a month for Ozempic, while this same exact drug can be purchased for just $155 in Canada, $122 in Denmark, and just $59 in Germany," said Sanders (I-Vt.). "Incredibly, Novo Nordisk also charges Americans with obesity $1,349 a month for Wegovy, while this same exact product can be purchased for just $186 in Denmark, $140 in Germany, and $92 in the United Kingdom."
"Wegovy is a 'game changer' weight loss drug. That doesn't mean much to the millions of people who can't afford it."
"The committee looks forward to Mr. Jørgensen answering a very simple question: Why does he think it's acceptable to charge Americans up to 10 or 15 times more for Ozempic and Wegovy than people in Europe and other major countries?" said the senator.
Sanders had been planning to hold a vote on subpoenaing Jørgensen before he indicated he would be open to testifying before the committee earlier this month.
In April, the North Carolina state health plan, used by 20,000 teachers and other state employees, announced it would discontinue coverage for Wegovy and similar medications because the price "would require them to double insurance premiums."
Earlier this month, Blue Cross Blue Shield of Michigan, the state's largest insurer, also said it would end coverage of glucagon-like peptide-1 (GLP-1) obesity drugs—a decision that could impact roughly 10,000 people in the state who use the medications.
"Wegovy is a 'game changer' weight loss drug," said Sanders at the time. "That doesn't mean much to the millions of people who can't afford it."
- Sanders Launches Probe of 'Outrageously Overpriced' Ozempic and Wegovy ›
- Sanders Warns 'Unjustifiably High' Prices of Weight Loss Drugs Could Bankrupt US Health System ›
- US Drug Prices Still Far Higher Than Other Nations' Even After Medicare Talks | Common Dreams ›
- Ahead of Senate Hearing, Doctors Decry 'Exorbitant' Cost of Ozempic and Wegovy | Common Dreams ›
- Sanders Calls BS on Novo Nordisk Excuses for Sky-High Prices of Ozempic, Wegovy | Common Dreams ›